Type 1 diabetes

In the paper

“Recent data suggest that although most patients with longstanding type 1 diabetes have few β cells, if any, there is evidence for β-cell regeneration in infants and very young children (but not in adolescents or adults).51,52”

What the sources say

• Partly supported

  The paper reports a burst of β-cell proliferation in the first two years of normal life, with little growth thereafter (Abstract; page unavailable). It does not establish regeneration in patients with longstanding type 1 diabetes or address how many β cells those patients retain. It also reports rare β-cell neogenesis in adolescents and adults, so the claim’s categorical exclusion of those ages is not supported. (LLM, conf=0.88)

  cites [51] Gregg, 2012, Formation of a human beta-cell population within pancreatic islets is set early in life, J Clin Endocrinol Metab sourceExperimental — accuracy not yet measured
• Disputed

  The Discussion (page unavailable in our copy) says β-cells can be replenished despite prolonged autoimmune stress and reports evidence of β-cell proliferation in people with type 1 diabetes for over 50 years. That is contrary to the claim that regeneration does not occur in adults. The paper does not establish the claimed contrast with infants and very young children. (LLM, conf=0.88)

  Checked by a reasoning model — may be wrong.

  cites [52] Keenan, 2010, Residual insulin production and pancreatic ß-cell turnover after 50 years of diabetes: Joslin Medalist Study, Diabetes sourceExperimental — accuracy not yet measured

In the paper

“Although type 1 diabetes can be diagnosed at any age, it is one of the most common chronic diseases of childhood.4”

What the sources say

• ?Could not verify

  The paper’s main text (page unavailable) discusses childhood-onset type 1 diabetes and reports rising incidence in Europe. It does not say whether type 1 diabetes is among the most common chronic diseases of childhood; searches for that phrase and for childhood disease prevalence found no comparison with other diseases. (LLM, conf=0.72)

  cites [4] Gale, 2005, Type 1 diabetes in the young: the harvest of sorrow goes on, Diabetologia sourceExperimental — accuracy not yet measured

In the paper

“However, not all patients with type 1 diabetes have these characteristics, leading to proposed classifications of type 1A (autoimmune) diabetes,41 for the 70–90% of patients with type 1 disease that have immunological, self-reactive autoantibodies, and type 1B (idiopathic) diabetes, representing the remainder whose specific pathogenesis remains unclear.42”

What the sources say

• Supported

  The opening section describes type 1A as immune-mediated and type 1B as a non-autoimmune, idiopathic form of type 1 diabetes. It also identifies anti-islet autoantibodies as markers distinguishing type 1A from other forms, supporting the distinction attributed to this source. (LLM, conf=0.92)

  cites [41] Eisenbarth, 2007, Update in type 1 diabetes, J Clin Endocrinol Metab source
• Partly supported

  The Introduction reports that about 15% of children presenting with new-onset diabetes produce no islet autoantibodies, and the Discussion says the causes of some other forms of childhood-onset diabetes need further study. The paper does not identify this entire remainder as type 1B (idiopathic) diabetes; it also discusses other possible forms, including type 2 and monogenic diabetes. No page numbers are available in our copy. (LLM, conf=0.83)

  cites [42] Gianani, 2010, Dimorphic histopathology of long-standing childhood-onset diabetes, Diabetologia sourceExperimental — accuracy not yet measured

In the paper

“Historically, type 1 diabetes was largely considered a disorder in children and adolescents, but this opinion has changed over the past decade, so that age at symptomatic onset is no longer a restricting factor.3”

What the sources say

• Supported

  In “Predicting Adult-Onset Autoimmune Diabetes” (page not supplied), the paper says the historical characterization of severe diabetes as childhood-onset was supplanted by classifications based on other features. Its Fig. 1 states that autoimmune diabetes extends across all ages, supporting the claim that age at onset is not a restricting factor. (LLM, conf=0.92)

  cites [3] Leslie, 2010, Predicting adult-onset autoimmune diabetes: clarity from complexity, Diabetes source

In the paper

“A 2011 study of adult-onset type 1 diabetes suggested that autoimmune type 1 diabetes in children and adults differs by just a few age-dependent genetic effects;48”

What the sources say

• Supported

  The Abstract’s Conclusions state that the results are consistent with the hypothesis that autoimmune diabetes in adults and children differs by only relatively few age-dependent genetic effects. The citing sentence preserves that tentative wording by saying the study “suggested” this conclusion. (LLM, conf=0.95)

  cites [48] Howson, 2011, Genetic analysis of adult-onset autoimmune diabetes, Diabetes source

In the paper

“In 2009, the American Diabetes Association modified their guidelines for diabetes diagnosis to include glycated haemoglobin (HbA1C; a test that averages blood glucose concentrations over 3 months) of 6·5% or higher.35”

What the sources say

• Partly supported

  The Recommendations and conclusions section recommends diagnosing diabetes at A1C ≥6.5%. But the opening section says the report represents the International Expert Committee’s views, not necessarily those of the American Diabetes Association, and invites professional organizations to consider its recommendations. It does not establish that the ADA modified its guidelines in 2009. (LLM, conf=0.89)

  cites [35] 2009, International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes, Diabetes Care sourceExperimental — accuracy not yet measured

In the paper

“if this is the case, perhaps as many as 50% of actual type 1 diabetes cases are misdiagnosed as type 2, meaning that the number of cases of type 1 disease is vastly underestimated.”

What the sources say

• Partly supported

  The ‘Latent Autoimmune Diabetes in Adults’ section (pp. S40–S45) reports LADA in some adults diagnosed with type 2 diabetes, including prevalence estimates of 4.2–13.2% in specified Caucasian populations. It does not estimate that 50% of actual type 1 cases are diagnosed as type 2 or conclude that type 1 case counts are vastly underestimated. Its discussion also treats LADA as heterogeneous, rather than equating every LADA case with type 1 diabetes. (LLM, conf=0.84)

  cites [36] Tuomi, 2005, Type 1 and type 2 diabetes: what do they have in common?, Diabetes sourceExperimental — accuracy not yet measured

In the paper

“For example, incidence in Estonia is less than one-third of the incidence in Finland, although the two countries are separated by less than 120 km.17”

What the sources say

• Partly supported

  The Results report mean childhood-onset type 1 diabetes incidence of 11.2 in Estonia and 37.7 in Finland during 1983–1998, making Estonia’s rate less than one-third of Finland’s. The passages found do not state that the countries are separated by less than 120 km. (LLM, conf=0.87)

  cites [17] Podar, 2001, Increasing incidence of childhood-onset type I diabetes in 3 Baltic countries and Finland 1983–1998, Diabetologia sourceExperimental — accuracy not yet measured

In the paper

“Both of these concepts of pathogenesis of type 1 diabetes have been debated.50,51”

What the sources say

• ?Not checked — no full text of the sourcecites [50] Butler, 2007, The replication of beta cells in normal physiology, in disease and for therapy, Nat Clin Pract Endocrinol Metab source
• Partly supported

  The passage labeled Abstract (page unavailable) reports occasional β-cell neogenesis in adults, which bears on the idea that β cells cannot regenerate. But the study examined normal human pancreases, not remaining β cells in type 1 diabetes, and our copy does not address whether autoimmune destruction is debated. (LLM, conf=0.78)

  cites [51] Gregg, 2012, Formation of a human beta-cell population within pancreatic islets is set early in life, J Clin Endocrinol Metab sourceExperimental — accuracy not yet measured

In the paper

“Genetic changes or more children being born from mothers with type 1 diabetes cannot solely explain such rapid rates of increased incidence.22”

What the sources say

• Partly supported

  The 'Temporal trends in incidence' section reports rising childhood type 1 diabetes incidence, and 'Childhood type 1 diabetes' offers environmental and lifestyle factors as potential explanations. This supports the broader point that genetics alone need not explain the increase, but the paper does not address whether an increase in births to mothers with type 1 diabetes could explain it. Page numbers were unavailable in our copy. (LLM, conf=0.78)

  cites [22] Soltesz, 2007, Worldwide childhood type 1 diabetes incidence—what can we learn from epidemiology?, Pediatr Diabetes sourceExperimental — accuracy not yet measured

In the paper

“In many countries, the rise in incidence of type 1 diabetes has fluctuated, although Sweden has recently seen incidence rates plateau.12”

What the sources say

• Partly supported

  The Results (Generalized additive models; page unavailable) report that Swedish childhood type 1 diabetes incidence leveled off during the last seven years studied. The paper also describes rising incidence in many countries and short-term variation, but it does not establish that the rise fluctuated in many countries. (LLM, conf=0.84)

  cites [12] Berhan, 2011, Thirty years of prospective nationwide incidence of childhood type 1 diabetes: the accelerating increase by time tends to level off in Sweden, Diabetes sourceExperimental — accuracy not yet measured

In the paper

“Type 1 diabetes is generally thought to be precipitated by an immune-associated, if not directly immune-mediated, destruction of insulin-producing pancreatic β cells.1,2”

What the sources say

• Supported

  In the section headed “HLA Molecules and Insulin Peptides” (page not provided), the review calls pediatric type 1 diabetes an autoimmune disease and describes autoreactive T cells directed at islet antigens. It also identifies cytotoxic T cells as central to type 1 diabetes etiology and cites evidence that they target insulin-producing beta cells for killing. This supports the citing sentence’s hedged account of immune-associated beta-cell destruction. (LLM, conf=0.89)

  cites [1] Todd, 2010, Etiology of type 1 diabetes, Immunity source
• Supported

  The Abstract (page not provided) states that type 1 diabetes occurs as a consequence of immune destruction of insulin-producing pancreatic β-cells. The Pathophysiology section (page not provided) also describes evidence that autoreactive T cells play a dominant role in disease initiation and progression. (LLM, conf=0.94)

  cites [2] Bluestone, 2010, Genetics, pathogenesis and clinical interventions in type 1 diabetes, Nature source

In the paper

“and type 1B (idiopathic) diabetes, representing the remainder whose specific pathogenesis remains unclear.42”

What the sources say

• Partly supported

  The Introduction (page unavailable) says most childhood-onset diabetes is immune-mediated type 1A and identifies other, less well-characterised forms. The Discussion (page unavailable) calls for further study of the causes of a distinct histological pattern. Neither passage identifies those cases as type 1B (idiopathic) or says they constitute the remainder of type 1 diabetes cases. (LLM, conf=0.79)

  cites [42] Gianani, 2010, Dimorphic histopathology of long-standing childhood-onset diabetes, Diabetologia sourceExperimental — accuracy not yet measured

In the paper

“Increases in incidence have not occurred equally across all age groups; in Europe, the most substantial increases have been noted in children younger than 5 years of age.5,21”

What the sources say

• ?Not checked — no full text of the sourcecites [5] Harjutsalo, 2008, Time trends in the incidence of type 1 diabetes in Finnish children: a cohort study, Lancet source
• Supported

  The Global trend section reports that the annual increase was greatest among children aged 0–4 (4.0%), compared with ages 5–9 (3.0%) and 10–14 (2.1%), and says this age pattern was seen mainly in European populations. The Discussion likewise describes a particularly rapid increase in the youngest European age groups. Page numbers are not supplied in our copy. (LLM, conf=0.94)

  cites [21] 2006, Incidence and trends of childhood type 1 diabetes worldwide 1990–1999, Diabet Med source

In the paper

“Type 1 diabetes is most common in Finland (>60 cases per 100 000 people each year) and Sardinia (around 40 cases per 100 000 people each year).16”

What the sources say

• Partly supported

  The Results table (page not available in our copy) shows high childhood type 1 diabetes incidence in two Finnish regions, but its highest reported rate is 52.6 per 100,000, not over 60. The paper does not report a rate for Sardinia, and its rates concern children aged 0–14 rather than people of all ages. (LLM, conf=0.85)

  cites [16] Patterson, 2009, Incidence trends for childhood type 1 diabetes in Europe during 1989–2003 and predicted new cases 2005–20: a multicentre prospective registration study, Lancet sourceExperimental — accuracy not yet measured

In the paper

“similarly, subtypes of type 2 diabetes in children are poorly characterised, particularly in minority populations in the USA.44”

What the sources say

• Partly supported

  The Comment section reports that some US youth clinically diagnosed with type 2 diabetes had positive autoantibodies and says their role among minority youth requires further exploration. This supports uncertainty about one aspect of type 2 diabetes in minority children, but does not establish the broader claim that its subtypes generally are poorly characterised. (LLM, conf=0.82)

  cites [44] Dabelea, 2007, Incidence of diabetes in youth in the United States, JAMA sourceExperimental — accuracy not yet measured

In the paper

“Other factors that complicate diagnosis of type 1 diabetes include the growing problem of obesity (both childhood and adult), difficulties in health-care provider recognition of disease, and increasingly diverse genetic admixtures due to migration and social changes.45–47”

What the sources say

• ?Not checked — no full text of the sourcecites [45] Wilkin, 2009, The accelerator hypothesis: a review of the evidence for insulin resistance as the basis for type I as well as type II diabetes, Int J Obes (Lond) source
• ?Not checked — no full text of the sourcecites [46] Soderstrom, 2012, Being born in Sweden increases the risk for type 1 diabetes—a study of migration of children to Sweden as a natural experiment, Acta Paediatr source
• ?Could not verify

  The Introduction discusses type 1 diabetes incidence, genetics and environmental factors, while the Study design describes how cases were identified and validated; neither addresses obstacles to diagnosis. Searches for obesity, provider recognition and genetic admixture due to migration found no passage linking them to diagnostic difficulty in our copy. (LLM, conf=0.75)

  cites [47] Puett, 2012, Neighborhood context and incidence of type 1 diabetes: the SEARCH for Diabetes in Youth study, Health Place sourceExperimental — accuracy not yet measured

In the paper

“A plethora of environmental influences have been purported to affect the epidemiology of type 1 diabetes,25 with infant and adolescent diets,26 vitamin D and vitamin D pathway constituents,27–29 and viruses receiving the most focus.30,31”

What the sources say

• ?Not checked — no full text of the sourcecites [25] Maclaren, 1992, Is insulin-dependent diabetes mellitus environmentally induced?, N Engl J Med source
• ?Not checked — no full text of the sourcecites [26] Knip, 2010, Infant feeding and the risk of type 1 diabetes, Am J Clin Nutr source
• Partly supported

  The Methods and Results (page unavailable) show that this study measured vitamin D status in youth who already had type 1 diabetes, supporting vitamin D as a topic of research in this population. It does not examine whether vitamin D or its pathway constituents influence the incidence or epidemiology of type 1 diabetes; the diet and virus portions have separate citations. (LLM, conf=0.82)

  cites [27] Svoren, 2009, Significant vitamin D deficiency in youth with type 1 diabetes mellitus, J Pediatr sourceExperimental — accuracy not yet measured
• Supported

  The citation is attached to the vitamin D and vitamin D pathway constituents portion of the sentence, not to diets or viruses. The paper’s Objective and Discussion (page numbers not provided) describe associations between type 1 diabetes and vitamin D levels, vitamin D pathway gene variants, and vitamin D–binding protein; it does not claim these relationships are causal. (LLM, conf=0.91)

  cites [28] Blanton, 2011, Reduced serum vitamin D-binding protein levels are associated with type 1 diabetes, Diabetes source
• Supported

  This source is cited for the vitamin D and vitamin D pathway constituents portion of the sentence, not for diets or viruses. The Conclusions and Discussion (page numbers not supplied) examine vitamin D status and report associations between vitamin D metabolism genes and type 1 diabetes risk. (LLM, conf=0.93)

  cites [29] Cooper, 2011, Inherited variation in vitamin D genes is associated with predisposition to autoimmune disease type 1 diabetes, Diabetes source

In the paper

“Thus, disease hetero geneity is an important asp of type 1 diabetes, and suggests a role for genetics, age at disease onset, and intensity of disease management on the ability to retain β-cell”

What the sources say

• Partly supported

  The Results and Discussion (page unavailable in our copy) show substantial variation in residual C-peptide and associate higher levels with HLA genotype, later age at onset, and better glycemic control. They do not assess the intensity of disease management or establish that management intensity affects retention of β-cell function; glycemic control is not the same measure. (LLM, conf=0.85)

  cites [84] Keenan, 2010, Residual insulin production and pancreatic ss-cell turnover after 50 years of diabetes: Joslin Medalist Study, Diabetes sourceExperimental — accuracy not yet measured

In the paper

“For example, in Mozambique, the life expectancy for a newly diagnosed child with type 1 diabetes is 7 months.123”

What the sources say

• Partly supported

  In “Estimates of prevalence and prognosis” (Table 2; page not specified), the paper estimates 0.6 years—about seven months—for a child aged 0–14 with insulin-requiring diabetes in rural Mozambique. The claim omits the rural restriction: the paper’s national estimate for that age group is 3.5 years. The table also does not specify newly diagnosed children with type 1 diabetes. (LLM, conf=0.90)

  cites [123] Beran, 2005, Access to care for patients with insulin-requiring diabetes in developing countries: case studies of Mozambique and Zambia, Diabetes Care sourceExperimental — accuracy not yet measured

In the paper

“These autoantibodies can appear as early as 6 months of age, with a peak incidence before 2 years of age in genetically susceptible individuals;66 thus, they are present months to years before symptomatic onset.”

What the sources say

• Partly supported

  The Results and Discussion report peak autoantibody incidence from 9 months to 2 years in genetically at-risk children. The claim that autoantibodies can appear as early as 6 months is not established by this study: the Discussion reports no seroconversion at 3 or 6 months in the BABYDIET cohort, while cautioning that its size cannot rule out occurrence then. The citation precedes the sentence’s concluding inference about symptomatic onset, so that inference is not part of the attributed claim. (LLM, conf=0.88)

  cites [66] Ziegler, 2012, Age-related islet autoantibody incidence in offspring of patients with type 1 diabetes, Diabetologia sourceExperimental — accuracy not yet measured

In the paper

“A trial comparing a sensor-augmented pump with multiple daily injection therapy showed significant improvement in HbA1C reduction with less hypoglycaemia in the sensor-augmented pump cohort.88,94”

What the sources say

• Partly supported

  The Results report a significantly greater HbA1c reduction with sensor-augmented pump therapy. But the Adverse Events section says hypoglycemia measures were similar between groups, and the Results report no significant difference in severe hypoglycemia rates; the claim of less hypoglycaemia is not supported. Page numbers were unavailable in our copy. (LLM, conf=0.90)

  cites [88] Bergenstal, 2010, Effectiveness of sensor-augmented insulin-pump therapy in type 1 diabetes, N Engl J Med sourceExperimental — accuracy not yet measured
• Partly supported

  The Abstract Conclusions report greater A1C reductions with sensor-augmented pump therapy than with multiple daily injections. The Results do not support the claim of less hypoglycaemia: in the continuation phase, severe hypoglycaemia rates were not significantly different between the continuing-pump and crossover groups. Our copy does not establish a lower hypoglycaemia rate for the pump cohort versus the injection cohort. (LLM, conf=0.88)

  cites [94] 2011, Sensor-augmented pump therapy for A1C reduction (STAR 3) study: results from the 6-month continuation phase, Diabetes Care sourceExperimental — accuracy not yet measured

In the paper

“A study in Finland128 identified 230 infants with a first-degree relative with type 1 diabetes, and randomly assigned infants to receive a hydrolysed infant formula or conventional formula whenever breast milk was not available during the first 6–8 months of life.”

What the sources say

• Supported

  Split into 2 atoms — 2 confirmed, 0 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.

  cites [128] Knip, 2010, Dietary intervention in infancy and later signs of beta-cell autoimmunity, N Engl J Med source

In the paper

“when comparing the safety and efficacy of overnight closed-loop delivery of insulin with conventional insulin-pump therapy in adults with type 1 diabetes, closed-loop delivery improved overnight control of glycaemia and reduced the risk of nocturnal hypoglycaemia.98,99”

What the sources say

• ?Not checked — no full text of the sourcecites [98] Garg, 2012, Reduction in duration of hypoglycemia by automatic suspension of insulin delivery: the in-clinic ASPIRE study, Diabetes Technol Ther source
• Partly supported

  Split into 2 atoms — 0 confirmed, 2 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.

  cites [99] Buckingham, 2010, Prevention of nocturnal hypoglycemia using predictive alarm algorithms and insulin pump suspension, Diabetes Care sourceExperimental — accuracy not yet measured

In the paper

“Lipid and metabolite profiles can also serve as markers for impending type 1 diabetes; these markers include decreased phosphatidylcholine at birth, and reduced triglycerides and antioxidant ether phospholipids followed by increased proinflammatory lysophosphatidylcholine several months before seroconversion to auto antibody positivity.70”

What the sources say

• Supported

  Split into 2 atoms — 2 confirmed, 0 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.

  cites [70] Oresic, 2008, Dysregulation of lipid and amino acid metabolism precedes islet autoimmunity in children who later progress to type 1 diabetes, J Exp Med source

In the paper

“A randomised controlled trial in adults with type 1 diabetes reported lower HbA1C concentrations with sensor-augmented pump therapy than with injection therapy, and a greater proportion of patients reaching the targeted levels of HbA1C.88”

What the sources say

• Supported

  The Methods describe a randomized controlled trial that included adults with type 1 diabetes. The Discussion reports that adults receiving sensor-augmented pump therapy had a greater reduction in glycated hemoglobin than those receiving injections, and that more pump-therapy patients reached the prespecified target. (LLM, conf=0.94)

  cites [88] Bergenstal, 2010, Effectiveness of sensor-augmented insulin-pump therapy in type 1 diabetes, N Engl J Med source

In the paper

“Metabolic changes in the natural history of type 1 diabetes are marked by decreased early C-peptide response at least 2 years before onset,80 increased glucose fluctuations as an individual approaches onset,81 and an overall linear rise, with a last-minute surge, in plasma glucose in”

What the sources say

• Partly supported

  Split into 3 atoms — 1 confirmed, 2 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.

  cites [80] Sosenko, 2010, Trends of earlier and later responses of C-peptide to oral glucose challenges with progression to type 1 diabetes in diabetes prevention trial-type 1 participants, Diabetes Care sourceExperimental — accuracy not yet measured
• Supported

  Citation 81 is attached to the claim about glucose fluctuations, not the neighboring claims about C-peptide or a last-minute glucose surge. The Discussion says glucose levels can fluctuate widely within an individual and that this pattern extends into higher glycemic ranges as type 1 diabetes onset approaches. (LLM, conf=0.92)

  cites [81] Sosenko, 2010, Glucose excursions between states of glycemia with progression to type 1 diabetes in the diabetes prevention trial-type 1 (DPT-1), Diabetes source
• Partly supported

  Split into 2 atoms — 0 confirmed, 2 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.

  cites [82] Ferrannini, 2010, Progression to diabetes in relatives of type 1 diabetic patients: mechanisms and mode of onset, Diabetes sourceExperimental — accuracy not yet measured

In the paper

“Of the many HLA types, HLA class II show the strongest association with type 1 diabetes, where haplotypes DRB1*0401-DQB1*0302 and DRB1*0301-DQB1*0201 confer the greatest susceptibility, and DRB1*1501 and DQA1*0102-DQB1*0602 provide disease resistance.74”

What the sources say

• Partly supported

  The Results (page not provided) place both named susceptibility haplotypes among the most susceptible and identify DRB1*1501-DQA1*0102-DQB1*0602 as highly protective. But DRB1*0405-DQA1*0301-DQB1*0302 has a higher reported odds ratio than either named susceptibility haplotype, so the claim that those two confer the greatest susceptibility overstates the risk ranking. The passages also do not compare the strength of class II associations with other HLA classes. (LLM, conf=0.86)

  cites [74] Erlich, 2008, HLA DR-DQ haplotypes and genotypes and type 1 diabetes risk: analysis of the type 1 diabetes genetics consortium families, Diabetes sourceExperimental — accuracy not yet measured

In the paper

“Leptin, the adipocyte hormone, might also benefit type 1 diabetes therapy via its ability to reverse a catabolic state through suppression of hypergluca-gonaemia.103”

What the sources say

• Supported

  In “Leptin can suppress glucagon levels and hyperglucagonemia is a hallmark feature of type 1 diabetes” (page unavailable), the paper reports that leptin reversed the diabetic state in insulin-deficient rodent models and that this effect was suggested to result from reduced plasma glucagon. Its discussion of relative leptin deficiency describes the energy-deficit and increased-lipolysis state in type 1 diabetes. The citing sentence’s “might” appropriately presents this as a potential therapeutic benefit, not an established clinical effect. (LLM, conf=0.85)

  cites [103] Oral, 2012, Leptin for type 1 diabetes: coming onto stage to be (or not?), Pediatr Diabetes source

In the paper

“GLP-1 might also prove beneficial, with studies noting that this incretin decreased peak postprandial glucose by 45% regardless of residual β-cell function.101”

What the sources say

• Supported

  The Abstract Conclusions state that exogenous GLP-1 decreased peak postprandial glucose by 45% in patients with type 1 diabetes regardless of residual β-cell function. The Discussion Conclusions repeat the finding and recommend investigating longer-term GLP-1 therapy, consistent with the cautious suggestion that it might prove beneficial. (LLM, conf=0.95)

  cites [101] Kielgast, 2011, Antidiabetic actions of endogenous and exogenous GLP-1 in type 1 diabetic patients with and without residual beta-cell function, Diabetes source

In the paper

“Not all individuals with anti-β-cell autoimmunity progress to overt disease (less than 5% who express a single type 1 diabetes-associated autoantibody progress41), for reasons unknown.”

What the sources say

• Partly supported

  The Prediction section (page unavailable) says that having at least two islet autoantibodies is highly predictive of progression, supporting the distinction between autoantibody expression and overt diabetes. It does not give a progression rate for people with a single autoantibody, so the claimed figure of less than 5% is unsupported. (LLM, conf=0.82)

  cites [41] Eisenbarth, 2007, Update in type 1 diabetes, J Clin Endocrinol Metab sourceExperimental — accuracy not yet measured

In the paper

“However, two studies have provided cost estimates specifically for type 1 diabetes, proposing an annual figure of $14·4–14·9 billion in the USA.104,105”

What the sources say

• ?Not checked — no full text of the sourcecites [104] Dall, 2009, Distinguishing the economic costs associated with type 1 and type 2 diabetes, Popul Health Manag source
• Supported

  The Abstract (Methodology/Principal Findings) estimates annual U.S. type 1 diabetes costs at $14.4 billion, and Table 11 in Discussion > Medical Costs gives the same total. This supports the $14.4 billion end of the range; the sentence cites two studies for the combined range, so it does not attribute the $14.9 billion figure to this paper alone. (LLM, conf=0.93)

  cites [105] Tao, 2010, Estimating the cost of type 1 diabetes in the US: a propensity score matching method, PLoS One source

In the paper

“a finding that might be explained by a recent report that, after myocardial infarction, patients with type 1 diabetes express antibodies to cardiac proteins, whereas patients with type 2 diabetes do not.111”

What the sources say

• Partly supported

  The Results section ('Discovery of a PIA syndrome in human T1D patients'; page not provided) reports cardiac autoantibodies in 15/18 post-MI patients with type 1 diabetes, supporting that part of the claim. It also reports them in 3/20 post-MI patients with type 2 diabetes, so the assertion that those patients do not express such antibodies is too absolute. (LLM, conf=0.92)

  cites [111] Gottumukkala, 2012, Myocardial infarction triggers chronic cardiac autoimmunity in type 1 diabetes, Sci Transl Med sourceExperimental — accuracy not yet measured

In the paper

“Although it is often stated that symptoms occur when 90–95% of β cells are lost, diagnosis of type 1 diabetes can occur when roughly two-thirds of the islets are devoid of insulin-producing cells.61,62”

What the sources say

• Partly supported

  The Patients section says nine children died within 24 hours of diagnosis, and the Results and Discussion report many insulin-deficient islets in their pancreases. But the available Table 1 text does not provide usable counts, and no passage establishes that roughly two-thirds of islets lacked insulin-producing cells at diagnosis. The Discussion’s separate “two-thirds” figure describes the A-cell composition of insulin-deficient islets, not the proportion of islets affected. (LLM, conf=0.82)

  cites [61] Foulis, 1984, The pancreas in recent-onset type 1 (insulin-dependent) diabetes mellitus: insulin content of islets, insulitis and associated changes in the exocrine acinar tissue, Diabetologia sourceExperimental — accuracy not yet measured
• ?Not checked — no full text of the sourcecites [62] Willcox, 2009, Analysis of islet inflammation in human type 1 diabetes, Clin Exp Immunol source

In the paper

“The hormone pramlintide has been shown to reduce postprandial hyperglycaemia, bodyweight, insulin dosage, and HbA1C concentrations, and to reduce postprandial glucagon and glucose excursions and slow gastric emptying.102”

What the sources say

• Supported

  The Chemistry and preclinical pharmacology section reports reduced postprandial glucagon release and glucose, along with slower gastric emptying. The Discussion reports lower A1C and modest weight loss, while the Phase II and Phase III type 1 diabetes sections report reduced insulin doses. The review notes that weight loss may be transient. (LLM, conf=0.92)

  cites [102] Ryan, 2009, Review of pramlintide as adjunctive therapy in treatment of type 1 and type 2 diabetes, Drug Des Devel Ther source

In the paper

“Although this endogenous secretion is typically low, maintenance is important since it is associated with less retinopathy and less severe hypoglycaemia at later stages of the disease.86”

What the sources say

• Partly supported

  The paper reports that sustained C-peptide (and thus insulin) secretion was associated with less retinopathy and fewer episodes of severe hypoglycemia in DCCT participants with type 1 diabetes (p. 1). It does not establish those associations specifically at later stages of disease; its discussion notes that most patients eventually lose β-cell function (p. 4). (LLM, conf=0.80)

  cites [86] Steffes, 2003, Beta-cell function and the development of diabetes-related complications in the diabetes control and complications trial, Diabetes Care sourceExperimental — accuracy not yet measured

In the paper

“Individuals with type 1 diabetes have a ten-times higher risk for cardiovascular events (eg, myocardial infarction, stroke, angina, and the need for coronary-artery revascularisation) than age-matched non-diabetic populations.107”

What the sources say

• Partly supported

  In “The Magnitude of the Problem” (page not available), the review reports a tenfold or greater increase in coronary heart disease mortality compared with U.S. national data. It also reports elevated coronary-event rates in people with type 1 diabetes, but does not establish a tenfold risk for the broader set of cardiovascular events listed in the citing sentence compared with age-matched people without diabetes. (LLM, conf=0.88)

  cites [107] Orchard, 2006, Type 1 diabetes and coronary artery disease, Diabetes Care sourceExperimental — accuracy not yet measured

In the paper

“This mechanism might help explain the differing rates of progression to type 1 diabetes in adults versus children, where only minor variations in genetic susceptibility have been noted.48”

What the sources say

• Supported

  The Conclusions state that adult and childhood autoimmune diabetes differ by relatively few age-dependent genetic effects. They also propose that adults’ slower progression toward autoimmune insulin deficiency is probably due to a lower overall genetic load and subtle differences in HLA associations and autoreactivity. The Discussion likewise describes largely shared genetic architecture. (LLM, conf=0.91)

  cites [48] Howson, 2011, Genetic analysis of adult-onset autoimmune diabetes, Diabetes source

In the paper

“Similarly, islet-cell transplantation depends on overcoming recurrent autoimmunity and averting alloimmunity.153”

What the sources say

• Partly supported

  The Conclusions and Discussion describe recurrent autoimmunity as a cause of graft loss despite immunosuppression. The Results also document rejection of a second pancreas graft, supporting the need to avert alloimmune rejection. However, the patients received pancreas-kidney transplants, not islet-cell transplants, so the claim extends the clinical finding to a different transplant setting. (LLM, conf=0.84)

  cites [153] Vendrame, 2010, Recurrence of type 1 diabetes after simultaneous pancreas-kidney transplantation, despite immunosuppression, is associated with autoantibodies and pathogenic autoreactive CD4 T-cells, Diabetes sourceExperimental — accuracy not yet measured

In the paper

“Therefore, islet transplantation remains an experimental procedure, with ongoing research focusing on new methods using biomaterials (eg, encapsulation), immune modulation, site of delivery, improved vascularisation, and more.151”

What the sources say

• Supported

  The Introduction describes islet transplantation as a therapy still being developed, with preliminary long-term results and a need to improve its effectiveness and availability. The Abstract and Engraftment section discuss the cited research directions: biomaterials, encapsulation, immunomodulation, alternative transplant sites, and revascularisation. (LLM, conf=0.86)

  cites [151] Gibly, 2011, Advancing islet transplantation: from engraftment to the immune response, Diabetologia source

In the paper

“Despite decades of investigation, the mechanisms by which β cells are eliminated or selectively destroyed (apart from antigen-specific immune responses) remain unclear.55”

What the sources say

• Partly supported

  The section on β-cell ‘suicide’ describes several possible contributors to selective destruction, including cytokine sensitivity and ER stress, while the section on immune-mediated destruction says multiple elimination pathways may operate together. The paper supports the idea that the process is not fully resolved, but it does not say that mechanisms apart from antigen-specific immune responses are simply unknown. (LLM, conf=0.78)

  cites [55] Atkinson, 2011, How does type 1 diabetes develop?: the notion of homicide or beta-cell suicide revisited, Diabetes sourceExperimental — accuracy not yet measured

In the paper

“In the past 5 years, interest in reversal of type 1 diabetes has grown.134”

What the sources say

• Partly supported

  The main text (page unavailable) describes expanding therapeutic approaches and pharmaceutical involvement, and Table 1 lists large trials seeking to reverse type 1 diabetes. This supports growing interest, but the paper describes developments over roughly a decade rather than establishing the claimed five-year period. (LLM, conf=0.82)

  cites [134] Greenbaum, 2011, Persistence is the twin sister of excellence: an important lesson for attempts to prevent and reverse type 1 diabetes, Diabetes sourceExperimental — accuracy not yet measured

In the paper

“To achieve progress with islet-cell transplantation, investigators are focusing on xenotransplantation, encapsulation, novel sites for cell delivery (eg, eye), and development of surrogate insulin-producing cells.151”

What the sources say

• Supported

  The Biomaterial scaffolds section discusses encapsulation and alternative delivery sites, including the anterior chamber of the eye. The Introduction and A multi-pronged approach for long-term success discuss xenogeneic islets and other insulin-producing cells as alternative cell sources. Page numbers are not provided in our copy. (LLM, conf=0.91)

  cites [151] Gibly, 2011, Advancing islet transplantation: from engraftment to the immune response, Diabetologia source

In the paper

“Despite knowledge gains that could allow for adopting this new set of terminologies for subgrouping cases of type 1 diabetes, the terms type 1A and type 1B diabetes are not commonly used;”

In the paper

“Diagnosis of diabetes has historically included fasting blood glucose higher than 7 mmol/L (126 mg/dL), any blood glucose of 11·1 mmol/L (200 mg/dL) or higher with symptoms of hyperglycaemia, or an abnormal 2 horal glucose-tolerance test.34”

What the sources say

• Not checked yetcites [34] 2012, Diagnosis and classification of diabetes mellitus, Diabetes Care

In the paper

“Over the past decade, knowledge of the pathogenesis and natural history of type 1 diabetes has grown substantially, particularly with regard to disease prediction and heterogeneity, pancreatic pathology, and epidemiology.”

In the paper

“Despite efforts to standardise diagnosis of type 1 diagnosis, the causes and typology remain unclear.”

In the paper

“Another dogma is that in patients with longstanding disease, the pancreas is devoid of insulin-producing cells and the remaining β cells are incapable of regeneration.”

In the paper

“and, globally, the quality of diabetes management remains uneven.”

In the paper

“Technological improvements in insulin pumps and continuous glucose monitors help patients with type 1 diabetes manage the challenge of lifelong insulin administration.”

In the paper

“An immediate need for exogenous insulin replacement is also a hallmark of type 1 diabetes, for which lifetime treatment is needed.”

In the paper

“The incidence of type 1 diabetes varies with seasonal changes and birth month.”

In the paper

“By contrast, the disorder is uncommon in China, India, and Venezuela (around 0·1 cases per 100 000 people each year).”

In the paper

“Polydipsia, polyphagia, and polyuria (the classic trio of symptoms associated with disease onset) along with overt hyperglycaemia remain diagnostic hallmarks in children and adolescents, and to a lesser extent in adults.”

In the paper

“However, despite broad organisational, intellectual, and fiscal investments, no means for preventing or curing type 1 diabetes exists”

In the paper

“Most cases of type 1 diabetes represent an immune, if not autoimmune-mediated disorder, meaning patients often show features of an immunological contribution to disease pathogenesis (eg, autoantibodies or genetic associations with genes controlling immune responses).”

In the paper

“Whereas most autoimmune disorders disproportionately affect women, type 1 diabetes is slightly more common in boys and men.6”

What the sources say

• ?Not checked — no full text of the sourcecites [6] Ostman, 2008, Gender differences and temporal variation in the incidence of type 1 diabetes: results of 8012 cases in the nationwide Diabetes Incidence Study in Sweden 1983–2002, J Intern Med source

In the paper

“Although type 1 diabetes can be diagnosed at any age, it is one of the most common chronic diseases of childhood.4”

In the paper

“Agents that show promise for averting debilitating disease-associated complications have also been identified.”

In the paper

“In terms of potential pathogenic mechanisms, CD8+ T cells are the most predominant population within the insulitis lesion, followed by (in declining order) macrophages (CD68+), CD4+ T cells, B lymphocytes (CD20+), and plasma cells (CD138+).62”

What the sources say

• ?Not checked — no full text of the sourcecites [62] Willcox, 2009, Analysis of islet inflammation in human type 1 diabetes, Clin Exp Immunol source

In the paper

“Examples include insulin degludec (recently approved for use in the EU, although approval declined by the US Food and Drug Administration), an analogue that might improve basal insulin administration in patients with type 1 diabetes, since it provides effective glycaemic control and reduces the risk of nocturnal hypoglycaemia.100”

What the sources say

• ?Not checked — no full text of the sourcecites [100] Heller, 2012, Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial, Lancet source

In the paper

“A meta-analysis has also shown that insulin pumps lower HbA1C concentrations more than multiple daily injections in adults with type 1 diabetes, with similar rates of hypoglycaemia.89”

What the sources say

• ?Not checked — no full text of the sourcecites [89] Yeh, 2012, Comparative effectiveness and safety of methods of insulin delivery and glucose monitoring for diabetes mellitus: a systematic review and meta-analysis, Ann Intern Med source

In the paper

“Surprisingly, FOXP3+ cells (ie, regulatory T cells; a population of intense research interest2) and natural killer cells are rare in this lesion.”

What the sources say

• ?Not checked — no full text of the sourcecites [62] Willcox, 2009, Analysis of islet inflammation in human type 1 diabetes, Clin Exp Immunol source

In the paper

“Fortunately, organisations such as the International Diabetes Federation, Life for a Child, Insulin for Life, and others are developing means to alleviate this disparity.”

In the paper

“Low-glucose suspend systems are currently available for clinical use in Europe, but remain in clinic trial testing in the USA.”

In the paper

“The discovery of insulin in 1921–22 was clearly the most significant therapeutic event in the history of type 1 diabetes;”

In the paper

“Nearly three decades have passed since the first immune-based therapies, using ciclosporin, were attempted to reverse type 1 diabetes.125”

What the sources say

• ?Not checked — no full text of the sourcecites [125] Bach, 2011, A historical view from thirty eventful years of immunotherapy in autoimmune diabetes, Semin Immunol source

In the paper

“The physical, social, and economic costs of type 1 diabetes are difficult to calculate, and attempts to quantify these variables typically do not distinguish between type 1 and type 2 disease.”

In the paper

“Therefore, continuous glucose monitoring is most appropriate for highly motivated patients with type 1 diabetes who are willing to wear the monitoring device, and those with continuous poor control during intensive insulin therapy.93”

What the sources say

• ?Not checked — no full text of the sourcecites [93] Ahmet, 2011, Prevalence of nocturnal hypoglycemia in pediatric type 1 diabetes: a pilot study using continuous glucose monitoring, J Pediatr source

In the paper

“Since type 1 diabetes is now a predictable disease, several large trials are investigating methods to prevent or delay the onset of disease.”

In the paper

“Efforts are underway to combine insulin pumps and continuous glucose monitors with a computer algorithm—ie, an integrated closed-loop system, or artificial pancreas (figure 5).”

In the paper

“Additionally, the nPOD effort attempts to extend investigations to the entire pancreas, rather than be limited by use of a biopsy sample.”

In the paper

“Although current sensor-augmented pump therapy uses each device independently, integration of both systems is being investigated.”

In the paper

“Once a critical mass (not well defined) of β cells is destroyed, symptomatic onset occurs, and the need for exogenous insulin replacement begins.”

In the paper

“Of the remaining loci, only those for the insulin VNTR, PTPN22, CTLA4, and IL2RA are associated with odds ratios greater than 1·1.75”

What the sources say

• ?Not checked — no full text of the sourcecites [75] Polychronakos, 2011, Understanding type 1 diabetes through genetics: advances and prospects, Nat Rev Genet source

In the paper

“Cardiovascular disease is becoming a more common macrovasular complication as individuals with in type 1 diabetes live longer.106”

What the sources say

• ?Not checked — no full text of the sourcecites [106] Melendez-Ramirez, 2010, Complications of type 1 diabetes, Endocrinol Metab Clin North Am source

In the paper

“Inequalities in the availability of technologies to reduce complications, improve quality of life, and improve diabetes manage ment (eg, HbA1C testing and blood-glucose monitoring) also raise ethical concerns.”

In the paper

“This classification seems appropriate in view of the ongoing disease processes and the near certainty that such individuals will eventually become symptomatic (insulin dependent).”

In the paper

“A model originally posed in 1986,77 updated in our 2001 article,78 and modified subsequently, poses that individuals are born with various degrees of genetic susceptibility for type 1 diabetes.”

What the sources say

• ?Not checked — no full text of the sourcecites [77] Eisenbarth, 1986, Type I diabetes mellitus. A chronic autoimmune disease, N Engl J Med source
• ?Not checked — no full text of the sourcecites [78] Atkinson, 2001, Type 1 diabetes: new perspectives on disease pathogenesis and treatment, Lancet source

In the paper

“Although this model has stood the test of time, some modifications should be considered due to knowledge gains (figure 4).”

In the paper

“Many practical and intellectual advances have been made since then, including improved metabolic testing, better understanding of disease pathogenesis, and availability of immune markers.126”

What the sources say

• ?Not checked — no full text of the sourcecites [126] van Belle, 2011, Type 1 diabetes: etiology, immunology, and therapeutic strategies, Physiol Rev source

In the paper

“The risk for microvascular complications, including retinopathy, nephropathy, and neuropathy, decreases with intensive insulin therapy.”

In the paper

“Over the past 5 years, several large clinical trials have advanced the prediction and prevention of microvascular complications (table 1).”

In the paper

“Therefore, preserving insulin secretion after disease onset is increasingly a therapeutic goal, and can involve intensive insulin therapy, mechanical technologies, or, as in several trials, immune intervention to disrupt β-cell destruction.”

In the paper

“This symptomatic onset happens after a silent phase that lasts for months to many years, that could, in genetically susceptible individuals with multiple autoantibodies, be considered asymptomatic type 1 diabetes.”

In the paper

“Efforts to prevent or cure type 1 diabetes are now done via large collaborative networks (eg, NIH TrialNet, Immune Tolerance Network, and Islet Cell Transplantation Consortium), with rigorous mechanistic assays and uniform protocols.”

In the paper

“Type 1 diabetes is clearly a polygenic disorder, with nearly 40 loci (so far) known to affect disease susceptibility.72”

What the sources say

• ?Not checked — no full text of the sourcecites [72] Concannon, 2009, Genetics of type 1A diabetes, N Engl J Med source

In the paper

“Tamborlane and colleagues91 reported that a real-time continuous glucose monitoring system decreased the amount of time spent in hypoglycaemia (<4 mmol/L [70 mg/dL]) and lowered HbA1C when used by patients an average of 6 days a week.”

What the sources say

• ?Not checked — no full text of the sourcecites [91] Tamborlane, 2008, Continuous glucose monitoring and intensive treatment of type 1 diabetes, N Engl J Med source

In the paper

“The Pittsburgh Epidemiology of Diabetes Complications study108 of type 1 diabetes reported cardiovascular events in adult patients younger than 40 years of age to be 1% per year, and three times higher in individuals older than 55 years.”

What the sources say

• ?Not checked — no full text of the sourcecites [108] Maser, 1991, Cardiovascular disease and arterial calcification in insulin-dependent diabetes mellitus: interrelations and risk factor profiles. Pittsburgh Epidemiology of Diabetes Complications Study-V, Arterioscler Thromb source

In the paper

“These results imply that single-agent immunosuppression alone might be insufficient to completely control the autoimmune destruction of β cells, or that more specific and targeted therapies are needed.”

In the paper

“In addition to preserving production of C-peptide, a key goal is to induce immune tolerance against β cells and thereby halt autoimmune destruction.”

In the paper

“Despite the advances in type 1 diabetes research and therapy, some researchers and clinicians are disappointed by a perceived lack of progress.”

In the paper

“Combination therapies that target several pathogenic pathways and improve β-cell viability might be needed to preserve endogenous insulin production in patients with type 1 diabetes.”

In the paper

“Other phase 2 studies of immune modulators showed evidence of therapeutic efficacy in settings of recent-onset type 1 diabetes; however, even with continued use, most did not show durable effects.”

In the paper

“Knowledge voids that have long existed for type 1 diabetes, unfortunately, remain today.”

In the paper

“Efforts are underway to assign specific phenotypes to genotypes, and to improve understanding of the genetic risk for type 1 diabetes by genotyping at multiple susceptibility loci.154”

What the sources say

• ?Not checked — no full text of the sourcecites [154] Winkler, 2012, A strategy for combining minor genetic susceptibility genes to improve prediction of disease in type 1 diabetes, Genes Immun source

In the paper

“Other agents used for secondary prevention, nicotinamide and intranasal insulin, have not been shown to delay or prevent diabetes onset.132,133”

What the sources say

• ?Not checked — no full text of the sourcecites [132] Gale, 2004, European Nicotinamide Diabetes Intervention Trial (ENDIT): a randomised controlled trial of intervention before the onset of type 1 diabetes, Lancet source
• ?Not checked — no full text of the sourcecites [133] Näntö-Salonen, 2008, Nasal insulin to prevent type 1 diabetes in children with HLA genotypes and autoantibodies conferring increased risk of disease: a double-blind, randomised controlled trial, Lancet source

In the paper

“Many of the limitations for islet transplantation hold true for another promising area, the use of stem cells as insulin-producing surrogates for β cells.”

In the paper

“but a post-hoc analysis suggested that individuals with high titre insulin autoantibodies benefited from treatment—it was estimated that diabetes onset was delayed as much as 5 years.131”

What the sources say

• ?Not checked — no full text of the sourcecites [131] Skyler, 2005, Effects of oral insulin in relatives of patients with type 1 diabetes: the Diabetes Prevention Trial—Type 1, Diabetes Care source